Physician profile
Sanjay Kumar
NPI 1174518633
$24,180.13
in general payments reported to CMS, 2019-2025
41 companies · $1,607 in 2025
The $1,607 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,743 · 2020: $3,741 · 2021: $3,269 · 2022: $3,372 · 2023: $2,752 · 2024: $2,696 · 2025: $1,607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,054.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,097.45 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $3,181.03 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $2,597.17 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $2,050.17 | 2019-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $1,784.74 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,110.16 | 2020-2025 | |
| Abbott Laboratories | $906.67 | 2019-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $903.48 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $813.49 | 2022-2025 | |
| Pfizer INC. | $812.58 | 2019-2025 | |
| Amarin Pharma, INC. | $715.05 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $661.19 | 2019-2022 | |
| Esperion Therapeutics, INC. | $454.73 | 2021-2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $436.30 | 2019-2025 | Jardiance, Synjardy |
| Allergan, INC. | $408.58 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.